<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11747323</article-id><article-id pub-id-type="pmc">2364027</article-id><article-id pub-id-type="pii">6692191</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Torrisi</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baglietto</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Johansson</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Veronesi</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name><surname>Bonanni</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guerrieri-Gonzaga</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ballardini</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name><surname>Decensi</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Chemoprevention, <label>2</label>Laboratory Medicine Unit, <label>3</label>Division of Epidemiology and Biostatistics and <label>4</label>Senology, European Institute of Oncology, via Ripamonti 435, Milan, 20141, Italy</aff><pub-date pub-type="ppub"><month>12</month><year>2001</year></pub-date><volume>85</volume><issue>12</issue><fpage>1838</fpage><lpage>1841</lpage><history><date date-type="received"><day>21</day><month>02</month><year>2001</year></date><date date-type="rev-recd"><day>29</day><month>08</month><year>2001</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The effect on the IGF system of 60&#x02008;mg and 600&#x02008;mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (<italic>P</italic> &#x0003c; 0.05) with no dose&#x02013;response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention.  &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>breast cancer prevention</kwd><kwd>SERMs</kwd><kwd>IGF system</kwd></kwd-group></article-meta></front></article>


